...
首页> 外文期刊>International Journal of Medical Sciences >Lentivirus-based RNA Silencing of Nemo-like Kinase (NLK) Inhibits the CAL 27 Human Adenosquamos Carcinoma Cells Proliferation and Blocks G0/G1 Phase to S Phase
【24h】

Lentivirus-based RNA Silencing of Nemo-like Kinase (NLK) Inhibits the CAL 27 Human Adenosquamos Carcinoma Cells Proliferation and Blocks G0/G1 Phase to S Phase

机译:Nemo样激酶(NLK)的基于慢病毒的RNA沉默抑制CAL 27人腺鳞癌细胞的增殖,并阻止G0 / G1期到S期

获取原文
           

摘要

Background: The Nemo-like kinase (NLK) is a serine/threonine-protein kinase that involved in a number of signaling pathways regulating cell fate. Variation of NLK has been shown to be associated with the risk of cancer. However, the function of NLK in oral adenosquamous carcinoma cells line CAL-27 is unknown. Methods: In this study, we evaluated the function of NLK in CAL-27 cells by using lentivirus-mediated RNA silence. The targeted gene expression, cell proliferation and cell cycle are investigated by RT-PCR, western-blot, MTT method, colony forming assay and flow cytometry analysis respectively. Results: After NLK silencing, the number of colonies was significantly reduced (54±5 colonies/well compared with 262±18 colonies/well in non-infected or 226±4 colonies/well in negative control group (sequence not related to NLK sequence with mismatched bases). Using crystal violet staining, we also found that the cell number per colony was dramatically reduced. The RNA silencing of NLK blocks the G0/G1 phase to S phase progression during the cell cycle. Conclusions: These results suggest that NLK silencing by lentivirus-mediated RNA interference would be a potential therapeutic method to control oral squamous carcinoma growth.
机译:背景:Nemo样激酶(NLK)是一种丝氨酸/苏氨酸蛋白激酶,参与调节细胞命运的许多信号通路。 NLK的变异已被证明与癌症风险有关。然而,NLK在口腔鳞状细胞癌细胞系CAL-27中的功能尚不清楚。方法:在这项研究中,我们通过慢病毒介导的RNA沉默评估了NLK在CAL-27细胞中的功能。分别通过RT-PCR,western-blot,MTT法,集落形成法和流式细胞术分析靶基因的表达,细胞增殖和细胞周期。结果:NLK沉默后,菌落数显着减少(54±5个菌落/孔,阴性对照组为262±18个菌落/孔,阴性对照组为226±4个菌落/孔(序列与NLK序列无关)结果表明,NLK的RNA沉默阻止了G0 / G1期向S期的进展。慢病毒介导的RNA干扰沉默可能是控制口腔鳞状细胞癌生长的潜在治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号